Burn J, Borthwick GM, Elliott F, Macrae F, Ong KR, Kraus AC et al.
Lancet Gastroenterol Hepatol 2026; 11: 760-774.
Among 1 866 individuals with Lynch syndrome, 100 mg aspirin was non-inferior to 600 mg in the intention-to-treat analysis (hazard ratio for time to first Lynch syndrome cancer 0.97, 95 per cent confidence interval 0.67 to 1.42), but this was not reproduced in the per-protocol analysis. Non-inferiority was not shown for 300 mg. Serious bleeding occurred in none on 100 mg versus 1.5 per cent on 600 mg.
Comment: Non-inferiority could not be formally concluded for lower doses of daily aspirin (100mg, 300mg) when compared to 600mg.
Comment by Jeongyoon (Jenny) Moon, MD
